Nancy Whiting, Pharm.D.


Nancy Whiting, Pharm.D., is Chief Executive Officer of Recludix Pharma and has an established track record in all phases of oncology drug development. Prior to Recludix, she was a 15-year veteran of Seagen where she served most recently as Executive Vice President of Corporate Strategy, Alliances, and Communication. Prior to this role at Seagen (formerly Seattle Genetics), Nancy served as Executive Vice President of Late Stage Development, Senior Vice President of Clinical Development and Medical Affairs, and Head of Experimental Medicine. During her tenure at Seagen, Nancy played a central role in the development and regulatory approvals of cancer medicines Adcetris® (brentuximab vedotin), Padcev® (enfortumab vedotin-ejfv), Tukysa® (tucatinib) and Tivdak® (tisotumab vedotin). She currently serves on the Board of Directors of Caribou Biosciences.

Prior to her career in the biopharmaceutical industry, Nancy practiced as a clinical oncology pharmacist at the Seattle Cancer Care Alliance. She received her Pharm.D. from the University of Washington and completed her undergraduate degree at the University of British Columbia.